.
rewards
-
.
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
while all of the drugs work on cgrp, they don�t all work the same way. three of them target the cgrp molecule itself. aimovig goes after cgrp's receptor in the brain. .
.
$17
OFF DEAL
OFF DEAL
GET DEAL
218 Used Today
50%
OFF DEAL
OFF DEAL
$20
OFF DEAL
OFF DEAL
GET DEAL
200 Used Today